Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
96.5M
-
Number of holders
-
143
-
Total 13F shares, excl. options
-
66.2M
-
Shares change
-
+64.5M
-
Total reported value, excl. options
-
$931M
-
Value change
-
+$906M
-
Put/Call ratio
-
0.55
-
Number of buys
-
136
-
Number of sells
-
-3
-
Price
-
$14.06
Significant Holders of AVADEL PHARMACEUTICALS PLC - Common Stock (AVDL) as of Q2 2024
160 filings reported holding AVDL - AVADEL PHARMACEUTICALS PLC - Common Stock as of Q2 2024.
AVADEL PHARMACEUTICALS PLC - Common Stock (AVDL) has 143 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 66.2M shares
of 96.5M outstanding shares and own 68.64% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (13.3M shares), Polar Capital Holdings Plc (6.56M shares), GENDELL JEFFREY L (5.74M shares), BlackRock Inc. (4.82M shares), VANGUARD GROUP INC (3.69M shares), BRAIDWELL LP (2.9M shares), WEALTH EFFECTS LLC (2.27M shares), CITADEL ADVISORS LLC (2.24M shares), Two Seas Capital LP (2.12M shares), and Woodline Partners LP (1.5M shares).
This table shows the top 143 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.